Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines

Cancer Investigation

Volumn 29, Issue 9, 2011, Pages 608-616

  Gangopadhyay, Nupur N ^a,b   Luketich, James D ^a,b   Opest, Amy ^a   Visus, Carmen ^a   Meyer, Ernest M ^a   Landreneau, Rodney ^a,b   Schuchert, Matthew J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Lung cancer; Signal transduction; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 9; CYTOCHROME C; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LD 50; LUNG CANCER; METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; WOUND HEALING;

APOPTOSIS; CASPASE 3; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 80054847634     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.621916     Document Type: Article

References (30)

1. American Cancer Society, Inc., Surveillance and Health Policy Research, Leading Sites of New Cancer Cases and Deaths- 2010 Estimates. American Cancer Society Website: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-026214.pdf; Accessed November, 2010.
2. Bolderson E, Richard DJ, Zhou BB, Khanna KK. Recent advances in cancer therapy targeting proteins involved in DNA doublestrand break repair. Clin Cancer Res 2009;15:6314-6320.
3. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421-440. (Pubitemid 40704125)
4. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009;89:23-40.
5. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980;283:593-596. (Pubitemid 10136042)
6. Alberts B. Redefining cancer research. Science 2009;325:1319.
7. Iglehart JD, Silver DP. Synthetic lethality - a new direction in cancer-drug development. N Engl J Med 2009;361:189-191.
8. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV,Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009;69:6381-6386.
9. Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, Izraeli S, et al. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer Res 2009;11:R78.
10. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010;70:8045-8054.
11. Salvati E, Scarsella M, Porru M, Rizzo A, Iachettini S, Tentori L, et al. PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. 2010;29:6280-6293.
12. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009;15:7277-7290.
13. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 2009;18:31-43.
14. Zhang J, Zhao D, Park HK,Wang H, Dyer RB, LiuW, et al. FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest 2010;120:1524-1534.
15. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, et al. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 2010;29:635-646.
16. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007;104:19482-19487.
17. NicolescuAC,Holt A, KandasamyAD, Pacher P, Schulz R. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem Biophys Res Commun 2009;387:646-650.
18. Carbone M, RossiMN, CavaldesiM, Notari A, Amati P, Maione R. Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells. Oncogene 2008;27:6083-6092.
19. Miknyoczki SJ, Jones-Bolin S, Pritchard S,HunterK, ZhaoH,Wan W, et al.Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol CancerTher 2003;2:371-382.
20. Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Rev Anticancer Ther 2010;10:1125-1136.
21. Zhang J, Wang X, Lin CJ, Couch FJ, Fei P. Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells. Cancer Biol Ther 2006;5:1632-1636.
22. Jacquemont C, Taniguchi T. Disruption of the Fanconi anemia pathway in human cancer in the general population. Cancer Biol Ther 2006;5:1637-1639.
23. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-8115. (Pubitemid 44299177)
24. Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Rep ir (Amst) 2008;7:2010-2019.
25. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci USA 2010;107:2201-2206.
26. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, et al.ThePARP inhibitor olaparib induces significant killing of ATM deficient lymphoid tumour cells in vitro and in vivo. Blood 2010;116:4578-4587.
27. Villa P, Kaufmann SH, EarnshawWC. Caspases and caspase inhibitors. Trends Biochem Sci 1997;22:388-393. (Pubitemid 27438202)
28. Albert JM, Cao C, Kim KW,Willey CD, Geng L, Xiao D, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-3042. (Pubitemid 46849580)
29. Quiles-Perez R, Munoz-Gamez JA, Ruiz-Extremera A, O'Valle F, Sanjuan-Nunez L, Martin-Alvarez AB, et al. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 2010;51:255-266.
30. Liang H, Tan AR. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs 2010;13:646-656.